Guangfen Mao1, Natthapol Songdej1, Deepak Voora1, Lawrence E Goldfinger1, Fabiola E Del Carpio-Cano1, Rachel A Myers1, A Koneti Rao2. 1. From Sol Sherry Thrombosis Research Center (G.M., N.S., F.E.D.C.-C., L.E.G., A.K.R.), Hematology Section, Department of Medicine (N.S., A.K.R.), and Department of Anatomy and Cell Biology (L.E.G.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; and Duke Center for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC (D.V., R.A.M.). 2. From Sol Sherry Thrombosis Research Center (G.M., N.S., F.E.D.C.-C., L.E.G., A.K.R.), Hematology Section, Department of Medicine (N.S., A.K.R.), and Department of Anatomy and Cell Biology (L.E.G.), Lewis Katz School of Medicine at Temple University, Philadelphia, PA; and Duke Center for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC (D.V., R.A.M.). koneti@temple.edu.
Abstract
BACKGROUND: PCTP (phosphatidylcholine transfer protein) regulates the intermembrane transfer of phosphatidylcholine. Higher platelet PCTP expression is associated with increased platelet responses on activation of protease-activated receptor 4 thrombin receptors noted in black subjects compared with white subjects. Little is known about the regulation of platelet PCTP. Haplodeficiency of RUNX1, a major hematopoietic transcription factor, is associated with thrombocytopenia and impaired platelet responses on activation. Platelet expression profiling of a patient with a RUNX1 loss-of-function mutation revealed a 10-fold downregulation of the PCTP gene compared with healthy controls. METHODS: We pursued the hypothesis that PCTP is regulated by RUNX1 and that PCTP expression is correlated with cardiovascular events. We studied RUNX1 binding to the PCTP promoter using DNA-protein binding studies and human erythroleukemia cells and promoter activity using luciferase reporter studies. We assessed the relationship between RUNX1 and PCTP in peripheral blood RNA and PCTP and death or myocardial infarction in 2 separate patient cohorts (587 total patients) with cardiovascular disease. RESULTS: Platelet PCTP protein in the patient was reduced by ≈50%. DNA-protein binding studies showed RUNX1 binding to consensus sites in ≈1 kB of PCTP promoter. PCTP expression was increased with RUNX1 overexpression and reduced with RUNX1 knockdown in human erythroleukemia cells, indicating that PCTP is regulated by RUNX1. Studies in 2 cohorts of patients showed that RUNX1 expression in blood correlated with PCTP gene expression; PCTP expression was higher in black compared with white subjects and was associated with future death/myocardial infarction after adjustment for age, sex, and race (odds ratio, 2.05; 95% confidence interval 1.6-2.7; P<0.0001). RUNX1 expression is known to initiate at 2 alternative promoters, a distal P1 and a proximal P2 promoter. In patient cohorts, there were differential effects of RUNX1 isoforms on PCTP expression with a negative correlation in blood between RUNX1 expressed from the P1 promoter and PCTP expression. CONCLUSIONS: PCTP is a direct transcriptional target of RUNX1. PCTP expression is associated with death/myocardial infarction in patients with cardiovascular disease. RUNX1 regulation of PCTP may play a role in the pathogenesis of platelet-mediated cardiovascular events.
BACKGROUND:PCTP (phosphatidylcholine transfer protein) regulates the intermembrane transfer of phosphatidylcholine. Higher platelet PCTP expression is associated with increased platelet responses on activation of protease-activated receptor 4thrombin receptors noted in black subjects compared with white subjects. Little is known about the regulation of platelet PCTP. Haplodeficiency of RUNX1, a major hematopoietic transcription factor, is associated with thrombocytopenia and impaired platelet responses on activation. Platelet expression profiling of a patient with a RUNX1 loss-of-function mutation revealed a 10-fold downregulation of the PCTP gene compared with healthy controls. METHODS: We pursued the hypothesis that PCTP is regulated by RUNX1 and that PCTP expression is correlated with cardiovascular events. We studied RUNX1 binding to the PCTP promoter using DNA-protein binding studies and humanerythroleukemia cells and promoter activity using luciferase reporter studies. We assessed the relationship between RUNX1 and PCTP in peripheral blood RNA and PCTP and death or myocardial infarction in 2 separate patient cohorts (587 total patients) with cardiovascular disease. RESULTS: Platelet PCTP protein in the patient was reduced by ≈50%. DNA-protein binding studies showed RUNX1 binding to consensus sites in ≈1 kB of PCTP promoter. PCTP expression was increased with RUNX1 overexpression and reduced with RUNX1 knockdown in humanerythroleukemia cells, indicating that PCTP is regulated by RUNX1. Studies in 2 cohorts of patients showed that RUNX1 expression in blood correlated with PCTP gene expression; PCTP expression was higher in black compared with white subjects and was associated with future death/myocardial infarction after adjustment for age, sex, and race (odds ratio, 2.05; 95% confidence interval 1.6-2.7; P<0.0001). RUNX1 expression is known to initiate at 2 alternative promoters, a distal P1 and a proximal P2 promoter. In patient cohorts, there were differential effects of RUNX1 isoforms on PCTP expression with a negative correlation in blood between RUNX1 expressed from the P1 promoter and PCTP expression. CONCLUSIONS:PCTP is a direct transcriptional target of RUNX1. PCTP expression is associated with death/myocardial infarction in patients with cardiovascular disease. RUNX1 regulation of PCTP may play a role in the pathogenesis of platelet-mediated cardiovascular events.
Authors: Thomas Bee; Kate Liddiard; Gemma Swiers; Sorrel R B Bickley; Chris S Vink; Andrew Jarratt; Jim R Hughes; Alexander Medvinsky; Marella F T R de Bruijn Journal: Blood Cells Mol Dis Date: 2009-05-21 Impact factor: 3.039
Authors: W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland Journal: Nat Genet Date: 1999-10 Impact factor: 38.330
Authors: Andrew L Frelinger; YouFu Li; Matthew D Linden; Marc R Barnard; Marsha L Fox; Douglas J Christie; Mark I Furman; Alan D Michelson Journal: Circulation Date: 2009-12-07 Impact factor: 29.690
Authors: G F Mao; L E Goldfinger; D C Fan; M P Lambert; G Jalagadugula; R Freishtat; A K Rao Journal: J Thromb Haemost Date: 2017-02-23 Impact factor: 5.824
Authors: Jia Qian Wu; Montrell Seay; Vincent P Schulz; Manoj Hariharan; David Tuck; Jin Lian; Jiang Du; Minyi Shi; Zhijia Ye; Mark Gerstein; Michael P Snyder; Sherman Weissman Journal: PLoS Genet Date: 2012-03-08 Impact factor: 5.917
Authors: Joëlle Michaud; Ken M Simpson; Robert Escher; Karine Buchet-Poyau; Tim Beissbarth; Catherine Carmichael; Matthew E Ritchie; Frédéric Schütz; Ping Cannon; Marjorie Liu; Xiaofeng Shen; Yoshiaki Ito; Wendy H Raskind; Marshall S Horwitz; Motomi Osato; David R Turner; Terence P Speed; Maria Kavallaris; Gordon K Smyth; Hamish S Scott Journal: BMC Genomics Date: 2008-07-31 Impact factor: 3.969
Authors: Leonard C Edelstein; Lukas M Simon; Raúl Teruel Montoya; Michael Holinstat; Edward S Chen; Angela Bergeron; Xianguo Kong; Srikanth Nagalla; Narla Mohandas; David E Cohen; Jing-fei Dong; Chad Shaw; Paul F Bray Journal: Nat Med Date: 2013-11-10 Impact factor: 53.440
Authors: S Janapati; J Wurtzel; C Dangelmaier; B K Manne; D Bhavanasi; J C Kostyak; S Kim; M Holinstat; S P Kunapuli; L E Goldfinger Journal: J Thromb Haemost Date: 2018-06-08 Impact factor: 5.824
Authors: Yinan Zheng; Brian T Joyce; Shih-Jen Hwang; Jiantao Ma; Lei Liu; Norrina B Allen; Amy E Krefman; Jun Wang; Tao Gao; Drew R Nannini; Haixiang Zhang; David R Jacobs; Myron D Gross; Myriam Fornage; Cora E Lewis; Pamela J Schreiner; Stephen Sidney; Dongquan Chen; Philip Greenland; Daniel Levy; Lifang Hou; Donald M Lloyd-Jones Journal: Circulation Date: 2022-06-02 Impact factor: 39.918
Authors: Jeremy G T Wurtzel; Sophia Lazar; Sonali Sikder; Kathy Q Cai; Igor Astsaturov; Andrew S Weyrich; Jesse W Rowley; Lawrence E Goldfinger Journal: PLoS One Date: 2021-12-22 Impact factor: 3.240
Authors: J Ong; A Faiz; W Timens; M van den Berge; M M Terpstra; K Kok; A van den Berg; J Kluiver; C A Brandsma Journal: Sci Rep Date: 2019-12-03 Impact factor: 4.379